NCT04702997 - A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

October 20, 2021

Study Completion Date

November 23, 2021

Conditions

Chronic Kidney Diseases

Interventions

DRUG

Bardoxolone methyl oral capsule

Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status

DRUG

Placebo oral capsule

Capsule containing an inert placebo

Trial Locations (12)

Columbia Nephrology Associates, PA, Columbia

Nephrology Center, PC, Kalamazoo

Renal Associates of Baton Rouge, Baton Rouge

Renal Disease Research Intitute, Dallas

DaVita Clinical Research, Houston

Clinical Advancement Center, PLLC, San Antonio

Gamma Medical Research Inc, McAllen

Western Nephrology, Arvada

Colorado Kidney Care, Denver

Boise Kidney & Hypertension, PLLC, Nampa

DaVita Clinical Research, Las Vegas

California Institute of Renal Research, La Mesa